Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 1.85 B
The data is delayed by 15 minutes.
CBM is in the long-term up 1220% in 15 years.
Description: Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products consist of active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products. The company serves generic drug companies, and companies that discover and commercialize new small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
|Shares Outstanding||31.98 M||EPS||2.85||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-20.81%||Sales Growth - Q/Q||-40.05%||P/E||20.14|
|P/E To EPS Growth||P/S||4.8||P/BV||7.6||Price/Cash Per Share|
|Price/Free Cash Flow||44.54||ROA||13.37%||ROE||26.34%||ROI||17.57%|
|Current Ratio||2.2||Quick Ratio||1.18||Long Term Debt/Equity||0.47||Debt Ratio||0.43|
|Gross Margin||35.31%||Operating Margin||16.19%||Net Profit Margin||16.66%||Dividend Payout Ratio|
|Cash From Financing Activities||1.6 M||Cash From Investing Activities||-12.04 M||Cash From Operating Activities||35.37 M||Gross Profit||29.08 M|
|Net Profit||7.99 M||Operating Profit||12.67 M||Total Assets||481.08 M||Total Current Assets||233.17 M|
|Total Current Liabilities||106.17 M||Total Debt||60 M||Total Liabilities||236.88 M||Total Revenue||77.53 M|
|High 52 week||68.4||Low 52 week||35.8||Last close||60||Last change||-0.25%|
|RSI||78.12||Average true range||2.66||Beta||1.21||Volume||174.76 K|
|Simple moving average 20 days||29.7%||Simple moving average 50 days||33.45%||Simple moving average 200 days||36.74%|
|Performance Week||44.89%||Performance Month||30.8%||Performance Quart||32.95%||Performance Half||52.21%|
|Performance Year||7.72%||Performance Year-to-date||58.9%||Volatility daily||8.53%||Volatility weekly||19.08%|
|Volatility monthly||39.11%||Volatility yearly||135.47%||Relative Volume||145.8%||Average Volume||405.21 K|
|New High||New Low|
2019-10-10 09:30:01 | ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
2019-09-25 17:17:30 | Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Highlands, Cambrex, Two River, and Carbon Black on behalf of Stockholders and Encourages Investors to Contact the Firm
2019-09-23 06:40:00 | Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement
2019-09-17 17:33:00 | Lifshitz & Miller LLP Announces Investigation of Avedro, Inc., Cambrex Corporation, Cardinal Health, Inc., Farfetch Limited Investors, Gannett Co., Inc., Pluralsight, Inc., Textron, Inc. and Vitamin Shoppe, Inc.
2019-09-13 09:40:01 | ALXN or CBM: Which Is the Better Value Stock Right Now?
2019-09-11 20:15:50 | Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Cambrex, Presidio, Old Line Bancorp, and Milacron Holdings on behalf of Stockholders and Encourages Investors to Contact the Firm
2019-08-26 09:30:01 | ALXN vs. CBM: Which Stock Is the Better Value Option?
2019-08-13 17:52:00 | CAMBREX INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cambrex Corporation - CBM
2019-08-09 20:00:00 | URGENT: Monteverde & Associates PC is Investigating the Following Transaction
2019-08-09 09:30:01 | ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
2019-08-08 16:54:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Cambrex Corp.
2019-08-08 14:11:32 | Cambrex's Earnings Outlook
2019-08-07 18:09:00 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Cambrex Corporation NYSE: CBM on Behalf of Cambrex Shareholders and Encourages Cambrex Investors to Contact the Firm
2019-08-07 14:10:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Cambrex Corporation
2019-08-07 10:02:37 | Cambrex Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Cambrex Corporation is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CBM
2019-08-07 09:13:27 | US STOCKS-Wall Street set to open lower as investors shun risk due to trade worries
2019-08-07 08:07:50 | Permira Funds To Acquire Cambrex In $2.4B Deal
2019-08-07 07:42:40 | US STOCKS-Futures advance as Trump plays down trade worries
2019-08-07 07:05:05 | UPDATE 1-Permira Funds to buy drug contract manufacturer Cambrex for $2.02 bln
2019-08-07 06:46:00 | Cambrex stock rockets after $2.4 billion buyout deal at a 60% premium
2019-08-07 06:41:39 | Permira Funds to buy contract manufacturer Cambrex in $2.4 bln deal